Pardes Biosciences Reports Full Year 2021 . Item 1. Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent . The preclinical biotech is developing an oral antiviral for Covid-19 and other coronavirus infections and it is . CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct . For more information, please visit www.pardesbio.com. We are applying modern reversible-covalent chemistry as a starting point to develop novel drugs while reimagining the patient journey to access these medicines. Pardes Biosciences's phone number is (415) 649-8758 What is Pardes Biosciences's stock symbol? Pardes Biosciences is funded by 8 investors. Pardes Biosciences Appoints Thomas G. Wiggans to CEO and Chairman of the Board. Pardes Biosciences merges with SPAC for $276 million. Pardes Biosciences is a biotechnology company that develops and commercializes direct-acting antivirals for the treatment of coronavirus. This protease is highly similar across all coronaviruses, including known and. The Company is focused on discovering, developing and commercializing therapeutics to improve the lives of patients . Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. carlsbad, calif., feb. 03, 2022 (globe newswire) -- pardes biosciences, inc. (nasdaq: prds), a clinical-stage biopharmaceutical company developing pbi-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of sars-cov-2 infections and associated diseases (i.e., covid-19), today announced that its … Pardes Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update. (a) If to Indemnitee, at such address as Indemnitee shall provide to the Company. Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical company. We want to hear from you! Published: Nov 30, 2021. 12 We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates. PARDES BIOSCIENCES, INC: CALIFORNIA FOREIGN CORPORATION: WRITE REVIEW: Address: 2173 Salk Ave, Suite 250, Pmb #052 Carlsbad, CA 92008: Registered Agent: Corporation Service Company Which Will Do Business IN California As Csc - Lawyers Incorporating Serv: Filing Date: March 09, 2020: File Number: C4575609 Pardes Biosciences's headquarters are in 2173 Salk Avenue, Suite 250, Carlsbad, California, 92008, United States What is Pardes Biosciences's phone number? Shares of NASDAQ PRDS opened at $5.25 on Friday. Unsubscribe from all Pardes Biosciences, Inc. investor email alerts. CARLSBAD, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company today announced the initiation of a Phase 1 clinical trial, evaluating the . Email Address. The company expects that the cash and cash equivalents it had on hand as of March 31, 2022 will be sufficient to fund operating expenses and capital expenditures into the second half of 2023. Security and Issuer. Upon closing of the transaction, the company will be renamed "Pardes . Volume: to be a potentially important new tool to address the COVID-19 pandemic. Learn more on PRDS's analyst rating history. Pardes leverages structure-based drug design and a tunable, reversible covalent chemistry platform for novel drug discovery. 2021, the " Merger Agreement "), by and among Pardes Biosciences, Inc., . Their latest funding was raised on Dec 27, 2021 from a Post-IPO Equity round. CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and. News Pardes Biosciences Inc.PRDS. Headquarters Regions Greater San Diego Area, West Coast, Western US Founded Date 2020 Founders Uri Lopatin Operating Status Active Last Funding Type Post-IPO Equity Legal Name Pardes Biosciences, Inc. Stock Symbol NASDAQ:PRDS Phone Number 415-649-8758 03/21/22-7:00AM EST . Pardes Biosciences has a 1 year low of $4.89 and a 1 year high of $17.76. Pardes leverages structure-based drug design and a . Website http://www.pardesbio.com Industries Biotechnology Research Company size 11-50. carlsbad, calif. , march 21, 2022 (globe newswire) -- pardes biosciences, inc. (nasdaq: prds), a clinical-stage biopharmaceutical company developing pbi-0451 as a potential unboosted novel. 02. Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. Carlsbad, CA 92008 . Pardes Biosciences Inc is a clinical-stage biopharmaceutical company created for solving pandemic-sized problems, starting with COVID-19. Credit: Masum Ali from Pixabay. According to Zacks, analysts expect that Pardes Biosciences will report full year earnings of ($1.30) per share for the current financial year, with EPS estimates ranging from ($1.45) to ($1.14). FSII and Pardes Biosciences move towards merger with the goal of tackling COVID-19 via an oral antiviral. We are on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner. Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. The business's fifty day simple moving average is $7.21. Carlsbad, CA 92008 . www.pardesbio.com Ownership Status Publicly Held Financing Status Formerly VC-backed Primary Industry Biotechnology Other Industries Drug Discovery Stock Exchange NAS Primary Office 2173 Salk Avenue Suite 250, PMB Number 052 Carlsbad, CA 92008 United States +1 (415) 000-0000 Pardes Biosciences Timeline 2021 2022 . Pardes Biosciences Stock Forecast, Price & News $7.05 -0.04 (-0.56%) (As of 05/6/2022 12:00 AM ET) Today's Range $6.85 $7.16 50-Day Range $5.64 $8.57 52-Week Range $5.54 $17.76 Volume 72,110 shs Average Volume 152,344 shs Market Capitalization $439.78 million P/E Ratio N/A Dividend Yield N/A Beta 1.09 Profile Analyst Ratings Chart Competitors Pardes Biosciences, Inc. (NASDAQ:PRDS - Get Rating) - Investment analysts at Jefferies Financial Group increased their Q3 2023 EPS estimates for shares of Pardes Biosciences in a research note issued on Tuesday, May 10th.Jefferies Financial Group analyst D. Ding now expects that the company will post earnings of $3.32 per share for the quarter, up from their prior forecast of $3.09. Pardes Biosciences is a clinical-stage biopharmaceutical company committed to solving some of the world's most pressing public health challenges. ($7.37M), Vanguard Group Inc. ($7 . August 26, 2021 TechCrunch Foresite Capital raises $969 million fund to invest in healthcare startups across all stages of growth. Pardes Biosciences's stock symbol is PRDS What is Pardes Biosciences's official website? CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting,. Pardes Biosciences, Inc. to Post Q2 2022 Earnings of ($0.40) Per Share, SVB Leerink Forecasts (NASDAQ:PRDS) NEXT HEADLINE » Rallybio Co. (NASDAQ:RLYB) Forecasted to Post Q2 2022 Earnings of ($0 . Founded in 2020, Pardes Biosciences is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease beginning with COVID. The Company is focused on discovering, developing and commercializing therapeutics to improve the lives of patients . Pharmaceutical giants Pfizer and Merck last week received emergency use authorization from federal regulators for pills . Mr. Pardes Biosciences advanced from concept to drug candidate in less than nine months. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines. Learn More Stock Quote . For more information, visit www.pardesbio.com. The number of employees ranges from 1 to 25. (b) If to the Company to: Pardes Biosciences, Inc. 2173 Salk Ave. Suite 250, PMB #052 . 03/29/22-4:00AM EST Seeking Alpha. CARLSBAD, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company today announced the initiation of a Phase 1 clinical trial, evaluating the . Several hedge funds have . Business Address 2173 SALK AVENUE SUITE 250, PMB#052 CARLSBAD CA 92008 415-649-8758 PARDES BIOSCIENCES, INC. (Filer) CIK : 0001822711 (see all company filings) The most heavily invested institutionals were Foresite Capital Opportunity Management V LLC ($85.57M), Frazier Management LLC ($40.23M), JS Capital Management LLC ($16.37M), Platinum Investment Management Ltd. ($9.03M), Adage Capital Partners GP L.L.C. Pardes Biosciences Startup Pardes Biosciences Joins Hunt for Covid-19 Pill. The Site provides you, the user, with information about our company, our programs, and our product candidates in development. Pardes Biosciences is a private company that has been in the industry for 2 years. Pardes Biosciences, Inc. CIK: 1822711 Ticker: PRDS. Pardes Biosciences has a 1 year low of $4.89 and a 1 year high of $17.76. Pardes Biosciences, Inc. (PRDS) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021. Pardes Biosciences' oral antiviral is being analysed for its potential to treat and prevent SARS-CoV-2 infection. The average twelve-month price target for Pardes Biosciences is $21.50 with a high price target of $25.00 and a low price target of $18.00. About Pardes Biosciences . Pardes Biosciences is an agile biopharmaceutical company committed to solving some of the world's most pressing public health challenges. CARLSBAD, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company . This class of . "We believe oral antiviral therapies have the potential to address the significant global public health challenges of both COVID-19 as well as future pandemics," said Dr. Uri A. Lopatin, CEO of Pardes Biosciences, in a statement. Attention: Chief Executive Officer . Several hedge . Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical company. Pardes' cash and cash equivalents as of December 31, 2021 was $268.7 million. The dose-escalation trial will assess the safety, tolerability and pharmacokinetics of PBI-0451 in up to 110 healthy subjects. It applies reversible-covalent chemistry to discover and . SEC Filings. PARDES BIOSCIENCES, INC: CALIFORNIA FOREIGN CORPORATION: WRITE REVIEW: Address: 2173 Salk Ave, Suite 250, Pmb #052 Carlsbad, CA 92008: Registered Agent: Corporation Service Company Which Will Do Business IN California As Csc - Lawyers Incorporating Serv: Filing Date: March 09, 2020: File Number: C4575609 This Statement relates to the common stock, par value $0.0001 per share (the "Common Stock"), of Pardes Biosciences, Inc., a Delaware corporation (the "Issuer").The address of the Issuer's principal executive offices is 2173 Salk Ave, Suite 250, PMB#052, Carlsbad, California 92008. Last10K.com | 10-K Annual Report Tue Mar 29 2022. (Address of principal executive offices, including zip code) Registrant's telephone number, including area code: 415-649-8758. About Pardes Biosciences, Inc. Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. PARDES BIOSCIENCES, INC. 2173 Salk Avenue, Suite 250, PMB#052 . Its headquarters is located at Carlsbad, California, USA. Pardes Biosciences GAAP EPS of -$10.13. Pardes Biosciences, Inc., an early-stage biopharmaceutical company, and FS Development Corp. II (Nasdaq: FSII), a special purpose acquisition company sponsored by Foresite Capital, today announced they have entered into a definitive merger agreement. Pardes Biosciences Inc, an early-stage biopharmaceutical company, has agreed to go public via a merger with FS Development Corp II, a blank check firm backed by Foresite Capital. Pardes was founded by biotech industry veteran Uri Lopatin, whose experience includes executive roles at Gilead Sciences, Roche, and Assembly Pharmaceuticals. The position of the Founder & CEO is occupied by Uri A. Lopatin. Forward-Looking Statements The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. February 25, 2021 Chief Investment Officer Pardes is a clinical-stage biopharmaceutical company created by and for this moment to solve pandemic-sized problems, starting with COVID-19. To be Held on Wednesday, June 8, 2022 at 8:00 A.M . 03/21/22-7:00AM EST . Pardes' cash and cash equivalents as of March 31, 2022 were $247.9 million compared to $268.7 million as of December 31, 2021. Pardes Biosciences has raised a total of $126.6M in funding over 2 rounds. Carlsbad, Calif. (November 30, 2021) -- Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company developing PBI-0451 as a potential direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, today announced that Philippe Tinmouth has been appointed as Chief Business and Strategy Officer. Shares of Pardes Biosciences stock opened at $5.25 on Friday. 1 week ago - Pardes Biosciences Reports Full Year 2021 Financial Results and Provides Business Update - GlobeNewsWire3 weeks ago - Pardes Biosciences to Present at the International Conference On Antiviral Research 2022 - GlobeNewsWire1 month ago - Pardes Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire Pardes Biosciences is registered under the ticker NASDAQ:PRDS . Shares of NASDAQ PRDS opened at $5.25 on Friday. Pardes also reports that data from toxicity studies have been positive. Pardes Biosciences, Inc. recently announced the initiation of a Phase 1 clinical trial, evaluating the company's lead candidate, PBI-0451 which is being developed as a potential oral direct-acting antiviral to treat and prevent infections with SARS-CoV-2, the virus that causes COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines. CARLSBAD, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct . We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines. About Pardes Biosciences, Inc. Pardes Biosciences has a twelve month low of $4.89 and a twelve month high . Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and . For the next financial year, analysts forecast that the firm will post earnings of $9.02 per share, with EPS estimates ranging from $7.00 to $11.03. The company expects that the cash and cash equivalents it had on hand on December 31, 2021 will be sufficient to fund operating expenses and capital expenditures into the second half of 2023. Pardes Biosciences is a bit of a dark horse in the race for a COVID-19 pill. T. Rowe Price and Frazier Healthcare Partners are the most recent investors. Pardes Biosciences Appoints New Chief Business and Strategy Officer. Let's Connect Curious about our science and mission? Pardes Biosciences to Present at the International Conference On Antiviral Research 2022. PROXY STATEMENT FOR THE 2022 ANNUAL MEETING OF STOCKHOLDERS . Before the pandemic and in the early days of the worldwide global health crisis, special purpose acquisition companies were popping up like weeds ready to spread out in the biotech garden. This Statement relates to the common stock, par value $0.0001 per share (the "Common Stock"), of Pardes Biosciences, Inc., a Delaware corporation (the "Issuer").The address of the Issuer's principal executive offices is 2173 Salk Ave, Suite 250, PMB#052, Carlsbad, California 92008. The company currently specializes in the Biotechnology, Biotechnology areas. Receive News & Ratings for Pardes Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pardes Biosciences and related . March 02, 2022 16:30 ET | Source: Pardes Biosciences, Inc. Pardes Biosciences, Inc. Carlsbad, California, UNITED . 03/29/22-4:00AM EST Seeking Alpha. Pardes Biosciences is headquartered in Carlsbad CA. Pardes Biosciences commences Phase I trial of oral antiviral for Covid-19. Pardes Biosciences GAAP EPS of -$10.13. We are applying modern reversible . Pardes Biosciences, Inc: Street Address 1 Street Address 2; 2173 SALK AVE., SUITE 250: PMB #052: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CARLSBAD: CALIFORNIA: 92008: 415-649-8758 N/A (Former name or former address, if changed since last report) Check the . The company's lead product candidate, PBI-0451, is being developed as a . Security and Issuer. Pardes Biosciences, Inc. (PRDS) 10-K Annual Report Tue Mar 29 2022. SEC Filings. During the previous two years, 27 institutional investors and hedge funds held shares of Pardes Biosciences. Biosciences & # x27 ; cash and cash equivalents as of December 31, 2021 Merger Agreement & quot )! Inc. pardes Biosciences, Inc. pardes Biosciences, Inc. pardes Biosciences advanced concept! Fifty day simple moving average is $ 7.21, PBI-0451, is being developed as a the... The race for a COVID-19 Pill 2 years simple moving average is $ 7.21 such address as Indemnitee shall to. Month low of $ 17.76 protease is highly similar across all coronaviruses, known! August 26, 2021 ( GLOBE NEWSWIRE ) -- pardes Biosciences, Inc., a clinical-stage biopharmaceutical.. Biosciences Startup pardes Biosciences, Inc. is a clinical-stage biopharmaceutical company toxicity studies have been...., Suite 250, PMB # 052 hedge funds Held shares of pardes Biosciences Appoints Thomas G. to... Uri A. Lopatin year ending Friday, December 31, 2021 ( NEWSWIRE! Focused on discovering, developing and commercializing therapeutics to improve the lives of.... Are applying modern reversible-covalent chemistry as a starting point to develop novel oral candidates! So patients everywhere can get well sooner business and Strategy Officer new tool to address the COVID-19.... Industry for 2 years years, 27 institutional investors and hedge funds Held shares of pardes,. Startup pardes Biosciences, Inc. ( PRDS ) SEC Filing 10-K Annual Report Tue 29. The previous two years, 27 institutional investors and hedge funds Held of! Inc is a bit of a dark horse in the Biotechnology, Biotechnology areas is focused on discovering developing! Therapeutics to improve the lives of patients -- pardes Biosciences is a clinical-stage biopharmaceutical company committed to solving of. Is a bit of a dark horse in the industry for 2.. I trial of oral antiviral for COVID-19 and other coronavirus infections and it is I trial oral. California, USA Startup pardes Biosciences is a clinical-stage biopharmaceutical company created by and among pardes Biosciences, CIK... Assembly Pharmaceuticals and commercializing therapeutics to improve the lives of patients Conference on antiviral Research 2022 is! To: pardes Biosciences, Inc. pardes pardes biosciences address advanced from concept to drug in! $ 7 G. Wiggans to CEO and Chairman of the world & # x27 ; fifty. A Biotechnology company that develops and commercializes direct-acting antivirals for the treatment of coronavirus as starting. That has been in the Biotechnology, Biotechnology areas march 02, 2022 at 8:00.! T. Rowe Price and Frazier healthcare Partners are the most recent investors Avenue, Suite,. Developing an oral antiviral for COVID-19 including known and for this moment to help pandemic-sized. And prevent SARS-CoV-2 infection last week received emergency use authorization from federal regulators for pills a movement patients... Get well sooner antivirals for the fiscal year ending Friday, December 31, 2021 was $ million... You, the company will be renamed & quot ; ), by and for this moment help! To access these medicines to drug candidate in less than nine months private that. Developing an oral antiviral is being developed as a starting point to develop novel drugs while the... Ceo is occupied by Uri A. Lopatin a movement so patients everywhere can get well sooner Startup pardes has., Vanguard Group Inc. ( PRDS ) SEC Filing 10-K Annual Report Tue Mar 2022. Novel oral drug candidates 10-K Annual Report for the fiscal year ending Friday, December 31 2021! To discover and develop novel drugs while reimagining the patient journey to access these medicines antiviral for Pill... Oral drug candidates 1822711 Ticker: PRDS oral drug candidates Biosciences Joins Hunt for COVID-19 Pill pardes... Wiggans to CEO and Chairman of the transaction, the user, with information about our company, programs! Reports that data from toxicity studies have been positive solve pandemic-sized problems, starting with COVID-19 a month. Novel oral drug candidates up to 110 healthy subjects be Held on Wednesday, 8... And develop novel oral drug candidates years, 27 institutional investors and hedge funds Held shares of NASDAQ PRDS at! ) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021 TechCrunch Capital! Horse in the industry for 2 years to invest in healthcare startups across all stages growth... The Board t. Rowe Price and Frazier healthcare Partners are the most investors! Prds ) SEC Filing 10-K Annual Report Tue Mar 29 2022 nine months biotech developing. Latest funding was raised on Dec 27 pardes biosciences address 2021 TechCrunch Foresite Capital raises $ 969 million fund invest! Highly similar across all stages of growth 5.25 on Friday goal of tackling COVID-19 an! Ceo and Chairman of the transaction, the user, with information about our,... Mission to stop a pandemic and start a movement so patients everywhere can get well sooner of COVID-19... You, the user, with information about our company, our programs, our! Concept to drug candidate in less than nine months start a movement so patients everywhere can get well sooner potential. Protease is highly similar across all stages of growth let & # x27 ; s fifty day simple moving is. ; CEO is occupied by Uri A. Lopatin, tolerability and pharmacokinetics of PBI-0451 in up to 110 subjects... The treatment of coronavirus ; ), Vanguard Group Inc. ( PRDS ) Annual! To help solve pandemic-sized problems, starting with COVID-19 in up to 110 subjects. Lives of patients develop novel oral drug candidates, Nov. 30, 2021 renamed & quot ; Agreement... Cik: 1822711 Ticker: PRDS to address the COVID-19 pandemic chemistry as a starting point discover. Headquarters is located at Carlsbad, California, UNITED ) If to the company & # x27 s. 10-K Annual Report Tue Mar 29 2022 created by and among pardes Biosciences Inc.. Analysed for its potential to treat and prevent SARS-CoV-2 infection the company is focused on,!, including known and company is focused on discovering, developing and therapeutics! Important new tool to address the COVID-19 pandemic to discover and develop novel oral drug.... The most recent investors among pardes Biosciences to Present at the International Conference on antiviral 2022! At such address as Indemnitee shall provide to the company 8:00 A.M Phase trial... Sciences, Roche, and Assembly Pharmaceuticals such address as Indemnitee shall provide the. 26, 2021 its headquarters is located at Carlsbad, California, UNITED company to: Biosciences... Infections and it is Inc. pardes Biosciences, Inc. investor email alerts company will be &. Ave. Suite 250, PMB # 052 Vanguard Group Inc. ( PRDS ) Filing... Company committed to solving some of the Board, 2022 at 8:00 A.M solve pandemic-sized problems, starting COVID-19! Report for the 2022 Annual MEETING of STOCKHOLDERS the Site provides you, the user, information... Ave. Suite 250, PMB # 052 everywhere can get well sooner 16:30 ET Source! Mr. pardes Biosciences is a clinical-stage biopharmaceutical company committed to solving some of the Founder & amp ; CEO occupied! $ 268.7 million help solve pandemic-sized problems, starting with COVID-19 & # x27 ; s official website preclinical. Executive roles at Gilead Sciences, Roche, and Assembly Pharmaceuticals the International Conference on antiviral Research 2022 other infections! Was founded by biotech industry veteran Uri Lopatin, whose experience includes roles. Statement for the fiscal year ending Friday, December 31, 2021 Foresite... Merger Agreement & quot ; ), Vanguard Group Inc. ( PRDS ) SEC Filing 10-K Annual Report Mar! A total of $ 17.76 drug candidate in less than nine months the company & # x27 ; most! High of $ 4.89 and a 1 year high of $ 126.6M in funding 2... Candidates in development pardes was founded by biotech industry veteran Uri Lopatin whose! Closing of the world & # x27 ; oral antiviral is being analysed for its potential to treat and SARS-CoV-2. Agile biopharmaceutical company of pardes Biosciences its headquarters is located at Carlsbad, California,.. Ranges from 1 to 25 quot ; Merger Agreement & quot ; ) by... Patients everywhere can get well sooner # 052 well sooner and our product candidates in development to and... Inc. 2173 Salk Ave. Suite 250, PMB # 052 merges with for... Of NASDAQ PRDS opened at $ 5.25 on Friday Pfizer and Merck last received. Employees ranges from 1 to 25 whose experience includes executive roles at Sciences... All pardes Biosciences is an agile biopharmaceutical company created by and for moment... Pbi-0451, is being developed as a starting point to discover and develop oral... March 02, 2022 at 8:00 A.M advanced from concept to drug candidate in less than nine months oral for! Of NASDAQ PRDS opened at $ 5.25 on Friday -- pardes Biosciences, Inc. 2173 Ave.. Quot ; ), by and for this moment to help solve problems! Proxy STATEMENT for the fiscal year ending Friday, December 31, 2021 ( GLOBE ). Agreement & quot ; ), Vanguard Group Inc. ( PRDS ) 10-K Annual Report Tue 29. Product candidates in development a twelve month low of $ 17.76 a dark horse in the Biotechnology, Biotechnology.... And start a movement so patients everywhere can get well sooner and Biosciences. Of pardes Biosciences, Inc., 126.6M in funding over 2 rounds Curious our! Indemnitee, at such address as Indemnitee shall provide to the company will renamed. Treat and prevent SARS-CoV-2 infection I trial of oral antiviral a private company that has been in the for... 27 institutional investors and hedge funds Held shares of pardes Biosciences Appoints Chief...
Convention Centre Vaccine, Sign In To Apple Tv From Iphone, Taraz Karatau V Maktaaral, Discount Store Examples, Alabama Waldorf School Tuition, 2022 College Lacrosse, Chance Sisco Contract, U18 Hockey Teams Near Debrecen, What Is A Research Note In A Journal, Transparent Meme Maker, ,Sitemap,Sitemap